[{"orgOrder":0,"company":"Formycon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Formycon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Not Applicable"},{"orgOrder":0,"company":"Formycon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Formycon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Not Applicable"},{"orgOrder":0,"company":"Formycon","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Formycon \/ Bioeq","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Bioeq"},{"orgOrder":0,"company":"Formycon","sponsor":"Formycon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Formycon","amount2":0.71999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.71999999999999997,"dosageForm":"Subcutaneous Injection","sponsorNew":"Formycon \/ Formycon","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Formycon"},{"orgOrder":0,"company":"Formycon","sponsor":"Athos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Formycon","amount2":0.71999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.71999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"Formycon \/ Athos Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Athos Therapeutics"},{"orgOrder":0,"company":"Formycon","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Formycon \/ Formycon","highestDevelopmentStatusID":"12","companyTruncated":"Formycon \/ Formycon"},{"orgOrder":0,"company":"Formycon","sponsor":"Fresenius SE & Co. KGaA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Formycon \/ Formycon","highestDevelopmentStatusID":"14","companyTruncated":"Formycon \/ Formycon"}]

Find Clinical Drug Pipeline Developments & Deals by Formycon

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Otulfi (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.

                          Brand Name : Otulfi

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 30, 2024

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Recipient : Fresenius SE & Co. KGaA

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : FYB202 (ustekinumab biosimilar) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin 23 for treatment of immune-mediated disorders.

                          Brand Name : FYB202

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 07, 2023

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Recipient : Fresenius Kabi AG

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The structure of the transaction will involve Formycon acquiring all the rights in FYB202, a biosimilar candidate for Stelara® (ustekinumab), as well as a 50% share in FYB201, a biosimilar candidate for Lucentis®2 (ranibizumab).

                          Brand Name : FYB202

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 10, 2022

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Athos Therapeutics

                          Deal Size : $720.7 million

                          Deal Type : Acquisition

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The structure of the transaction will involve Formycon acquiring all the rights in FYB202, a biosimilar candidate for Stelara® (ustekinumab), as well as a 50% share in FYB201, a biosimilar candidate for Lucentis®2 (ranibizumab).

                          Brand Name : FYB202

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 29, 2022

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Recipient : Athos

                          Deal Size : $720.7 million

                          Deal Type : Acquisition

                          blank

                          05

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The aim of the randomized, double-blind, multi-center Phase III study is to demonstrate the comparability of FYB202 and the reference product Stelara(R) in terms of efficacy, safety and immunogenicity in patients with moderate to severe psoriasis vulgari...

                          Brand Name : FYB202

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 09, 2020

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Bioeq IP AG

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Formycon continues to work with license partner Bioeq AG and its manufacturing partner on the resubmission of the Biologics License Application (BLA) for the FYB201 project, a biosimilar candidate for Lucentis(R)* (Ranibizumab), despite the situation reg...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 15, 2020

                          Lead Product(s) : Ranibizumab

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Bioeq has decided to withdraw its BLA application for the Lucentis® biosimilar candidate, provide the requested data and resubmit the application thereafter, which may delay the approval of the BLA.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 04, 2020

                          Lead Product(s) : Ranibizumab

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank